SLXP Key Stats
| Income Statement | |
| Revenue TTM | 735.44M |
| Revenue Quarterly YoY Growth | 27.70% |
| EPS Diluted TTM | 1.006 |
| EPS Diluted Quarterly YoY Growth | -45.91% |
| Net Income TTM | 64.25M |
| Profitability | |
| Gross Profit Margin Quarterly | 84.52% |
| Profit Margin Quarterly | 8.89% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 3.645B |
| Enterprise Value | 3.838B |
| PE Ratio TTM | 59.22 |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 6.503 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 1.714 |
| Free Cash Flow | -9.008M |
| Return on Equity | 12.25% |
SLXP News
- Salix Pharma (SLXP) Reports Positive Results From Two Budesonide Foam Phase 3s Street Insider 7:02 AM
- AbbVie Extends Galapagos Deal - Analyst Blog Zacks 6:40 AM
- Positive Data on Novartis' Afinitor - Analyst Blog Zacks May 21
- Positive Data on Novo Nordisk's N9-GP - Analyst Blog Zacks May 21
- Positive Data on Novartis' Afinitor May 21
- Actavis to Buy Warner Chilcott - Analyst Blog Zacks May 21
- Positive Data on Novo Nordisk's N9-GP May 21
- Actavis to Buy Warner Chilcott May 21
- JNJ's Simponi Label Expanded - Analyst Blog Zacks May 21
- JNJ's Simponi Label Expanded May 21
SLXP Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Salix Pharmaceuticals is up 19.29% over the last year vs S&P 500 Total Return up 30.46%, Valeant Pharmaceuticals International up 60.20%, and Progenics Pharmaceuticals down 49.44%.
SLXP Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Cash Flow Statement View Statement
You may also be interested in these SLXP related companies
Pro Ratings for SLXP
Pro Report PDF for SLXP
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download SLXP Pro Report PDF
Pro Strategies Featuring SLXP
Did Salix Pharmaceuticals make it into our Pro Portfolio Strategies?
SLXP Profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Salix Pharmaceuticals Ltd. develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. Salix also markets OSMOPREP Tablets, VISICOL Tablets, APRISO extended-release capsules, METOZOLV, RELISTOR Subcutaneous Injection, PEPCID for Oral Suspension, Oral Suspension DIURIL, AZASAN Tablets, USP, ANUSOL-HC, ANUSOL-HC Suppository, PROCTOCORT Cream and PROCTOCORT Suppository. Crofelemer, budesonide foam, RELISTOR, Lumacan and rifaximin for additional indications are under development. It was founded by Randy W. Hamilton and Lorin K. Johnson in 1989 and is headquartered in Raleigh, North Carolina.
Other SLXP Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SLXP | 59.61 | +0.28 | +0.47% | 3.645B |
